131I ablation treatment in young females after the chernobyl accident

Journal of Nuclear Medicine

Volumn 47, Issue 10, 2006, Pages 1723-1727

  Travis, Curtis C ^a,c   Stabin, Michael G ^b  

^a SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

131I; Ablation treatment; Breast cancer; Chernobyl; Thyroid cancer

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADOLESCENT; ARTICLE; ATOMIC BOMB; BONE MARROW; BREAST CANCER; CANCER RISK; CHERNOBYL ACCIDENT; COMPUTER ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RADIATION DOSE; SCHOOL CHILD; SOLID TUMOR; THYROID CANCER; THYROID GLAND; ADULT; BREAST TUMOR; CHILD; ELECTRIC POWER PLANT; RADIATION ACCIDENT; RADIATION INJURY; RADIOTHERAPY; THYROID TUMOR; UKRAINE; WHOLE BODY COUNTING;

ACCIDENTS, RADIATION; ADOLESCENT; ADULT; BREAST NEOPLASMS; CHERNOBYL NUCLEAR ACCIDENT; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; NEOPLASMS, RADIATION-INDUCED; POWER PLANTS; RADIOTHERAPY; THYROID NEOPLASMS; UKRAINE; WHOLE-BODY COUNTING;

EID: 35148848270     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280:347-355.
2. Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer. 1991;64:159-163.
3. Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer. 1992;50:886-890.
4. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet. 1999;353:2111-2115.
5. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371-1377.
6. 131I for thyroid cancer. J Nucl Med. 1976;17:460-464.
7. van Santen HM, Aronson DC. Vulsma T, et al. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. Eur J Cancer. 2004;40:1743-1751.
8. Oliynyk V, Epshtein O, Sovenko T, et al. Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. J Endocrinol Invest. 2001;24:445-447.
9. 131I therapy. Radiat Environ Biophys. 2004;43:7-13.
10. Age-dependent doses to members of the public from intake of radionuclides: part 1 - report of a Task Group Committee of the International Commission on Radiological Protection. Ann ICRP. 1989;20:1-122.
11. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994;78:188-196.
12. Park S-G, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidism [abstract]. J Nucl Med. 1996;37(suppl):15P.
13. Menzel C, Kranert WT, Dobert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J Nucl Med. 2003;44:1065-1068.
14. 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements. Nucl Med Commun. 2005;26:623-631.
15. 131I in thyroid cancer patients. Health Phys. 2001;81:325-329.
16. Seabold JE, Ben-Haim S, Pettit WA, et al. Diuretic-enhanced I-131 clearance after ablation therapy for differentiated thyroid cancer. Radiology. 1993;187:839-842.
17. 131I. J Nucl Med. 2002;43:61-65.
18. 131I. J Nucl Med. 2003;44:898-903.
19. M'Kacher R, Legal JD, Schlumberger M et al. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. J Nucl Med. 1996;37:1860-1864.
20. Kramer GH, Hauck BM, Chamberlain MC. Biological half life of iodine in normal and athyroidic persons. Radiat Prot Dosimetry. 2002;102:129-135.
21. 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med. 2004;45:1549-1554.
22. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
23. 132I as sodium iodide. J Nucl Med. 1975;16:857-860.
24. National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: National Academies Press; 2006:550.
25. National Council on Radiation Protection and Measurements. Induction of thyroid cancer by ionizing radiation: recommendations of the National Council on Radiation Protection and Measurements. NCRP Report No. 80, Bethesda, MD: The Council; 1985.
26. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220-235.
27. Land CE, Tokunaga M, Koyama K, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res. 2003;160:707-717.
28. Boice JD Jr. Radiation and breast carcinogenesis. Med Pediatr Oncol. 2001;36:508-513.
29. Thompson DE, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987. Radiat Res. 1994;137(2, suppl l)S17-S67.
30. Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute; 2005.
31. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res. 2005;7:21-32.
32. 132Te). Health Phys. 2004;86:565-585.
33. Davis S, Stepanenko V, Rivkind N, et al. Risk of thyroid cancer in the Bryansk Oblast of the Russian Federation after the Chernobyl Power Station accident. Radiat Res. 2004;162:241-248.
34. 131I in childhood. J Natl Cancer Inst. 2005;97:724-732.
35. Pacini F, Vorontsova T, Demidchik EP, et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab. 1997;82:3563-3569.
36. Birrell G, Cheetham T. Juvenile thyrotoxicosis: can we do better? Arch Dis Child. 2004;89:745-750.